STAT June 21, 2024
Jason Mast, Matthew Herper

For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy.

On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sarepta’s Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA approves 1st RSV vaccine for adults under 60
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
FDA Approves Stelara Biosimilar Selardsi for Additional Indications
Pfizer gets a leg up in RSV as FDA clears jab for all adults
Novo Nordisk to FDA: Ozempic, Wegovy too complex to be copied

Share This Article